Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

ClinicalTrials.gov ID: NCT05952024

Public ClinicalTrials.gov record NCT05952024. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 2:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)

Study identification

NCT ID: NCT05952024
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 80 participants

Conditions and interventions

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

Acalabrutinib Drug
Rituximab Biological

Drug · Biological

Eligibility (public fields only)

Age range: 65 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 15, 2024
Primary completion: Mar 24, 2029
Completion: Mar 24, 2029
Last update posted: May 4, 2026

2024 – 2029

United States locations

U.S. sites: 14
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
Research Site	Berkeley	California	94704	Withdrawn
Research Site	La Jolla	California	92093	Completed
Research Site	Orange	California	92868	Recruiting
Research Site	Stamford	Connecticut	06902	Withdrawn
Research Site	Jacksonville	Florida	32256	Active, not recruiting
Research Site	Des Moines	Iowa	50309	Recruiting
Research Site	Lexington	Kentucky	40536	Withdrawn
Research Site	Beltsville	Maryland	20705	Active, not recruiting
Research Site	Towson	Maryland	21204	Active, not recruiting
Research Site	Detroit	Michigan	48202	Active, not recruiting
Research Site	Sioux Falls	South Dakota	57104	Withdrawn
Research Site	Lubbock	Texas	79410	Active, not recruiting
Research Site	Olympia	Washington	98506	Active, not recruiting
Research Site	Tacoma	Washington	98405	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05952024, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 4, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05952024 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →